MRK - Merck & Co Inc Stock Price, Fair Value and News

125.30USD-0.55 (-0.44%)Market Closed

Market Summary

USD125.30-0.55

Market Closed

-0.44%

MRK Stock Price

View Fullscreen

MRK RSI Chart

MRK Valuation

Market Cap

317.4B

Price/Earnings (Trailing)

137.62

Price/Sales (Trailing)

5.17

EV/EBITDA

59.64

Price/Free Cashflow

29.26

MRK Price/Sales (Trailing)

MRK Profitability

EBT Margin

6.37%

Return on Equity

5.71%

Return on Assets

2.18%

Free Cashflow Yield

3.42%

MRK Fundamentals

MRK Revenue

Revenue (TTM)

61.4B

Rev. Growth (Yr)

8.89%

Rev. Growth (Qtr)

7.82%

MRK Earnings

Earnings (TTM)

2.3B

Earnings Growth (Yr)

68.81%

Earnings Growth (Qtr)

488.42%

Breaking Down MRK Revenue

Last 7 days

-0.4%

Last 30 days

-4.7%

Last 90 days

-4.5%

Trailing 12 Months

19.0%

How does MRK drawdown profile look like?

MRK Financial Health

Current Ratio

1.25

Debt/Equity

0.77

Debt/Cashflow

0.47

MRK Investor Care

Dividend Yield

2.35%

Dividend/Share (TTM)

2.96

Buy Backs (1Y)

0.18%

Diluted EPS (TTM)

0.9

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	61.4B	0	0	0
2023	57.9B	58.3B	59.3B	60.1B
2022	54.0B	57.2B	59.0B	59.3B
2021	41.0B	43.0B	45.2B	48.7B
2020	40.4B	38.0B	36.5B	42.4B
2019	43.1B	44.4B	46.0B	39.1B
2018	40.7B	41.3B	41.7B	42.3B
2017	39.9B	40.0B	39.8B	40.1B
2016	39.4B	39.4B	39.9B	39.8B
2015	41.4B	40.2B	39.8B	39.5B
2014	43.6B	43.5B	43.1B	42.2B
2013	46.2B	44.9B	44.5B	44.0B
2012	48.2B	48.4B	47.8B	47.3B
2011	46.1B	47.0B	47.8B	48.0B
2010	33.5B	38.9B	44.0B	46.0B
2009	24.6B	25.6B	27.0B	27.4B
2008	0	24.1B	24.0B	23.9B
2007	0	0	0	24.2B

Get all data in R, Python etc through our Historical Stock Data APIs

About Merck & Co Inc

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

CEO	Mr. Robert M. Davis J.D.
WEBSITE	merck.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	65535

Merck & Co Inc Frequently Asked Questions

What is the ticker symbol for Merck & Co Inc? What does MRK stand for in stocks?

MRK is the stock ticker symbol of Merck & Co Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Merck & Co Inc (MRK)?

As of Fri Jul 26 2024, market cap of Merck & Co Inc is 317.36 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MRK stock?

You can check MRK's fair value in chart for subscribers.

Is Merck & Co Inc a good stock to buy?

The fair value guage provides a quick view whether MRK is over valued or under valued. Whether Merck & Co Inc is cheap or expensive depends on the assumptions which impact Merck & Co Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRK.

What is Merck & Co Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, MRK's PE ratio (Price to Earnings) is 137.62 and Price to Sales (PS) ratio is 5.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRK PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Merck & Co Inc's stock?

In the past 10 years, Merck & Co Inc has provided 0.114 (multiply by 100 for percentage) rate of return.